NOTICE OF UPGRADE

Our websites will be unavailable between the hours of AEST 4AM September 17, 2022 and AEST 11PM on date September 18, 2022

InvestoGain Australia
 

SEARCH LISTED COMPANY


Any AUS or NZ company

Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

SEARCH PRIVATE COMPANY


SEARCH FUNDS

Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:

EBR SYSTEMS INC. (EBR)

Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names

 

Shareholder links

Our website ranking of EBR: rating 3
(3 out of 5)
COMPANY WEBSITE:

 

REGISTRY:

Computershare Melbourne
Yarra Falls, 452 Johnston Street, Abbotsford VIC 3067
Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 3 9473 2500
RegistryWebsite RegistryEmail

Company details

ISIN: AU0000182552
Address: 480 Oakmead Parkway Sunnyvale, CA 94085 USA
Tel:  +1 408-720-1906Fax: +1 408-720-1996

Date first listed: 24/11/2021
Company Secretary: Brendan Case, John H Sellers (Joint Co Sec)
Activities: Medical device company focussed on developing and bringing to market, devices to treat patients with certain types of heart failure

News & Events

Expand this box to read and print

The suspension of trading in the securities of EBR Systems Inc. will be lifted immediately following the release by EBR of an update in relation to its WiSE Device.

21/10/2022

The company releases a Shareholder and Investor Webinar Presentation.

21/10/2022

EBR has identified a potential increased rate of battery depletion caused by the transmitter in some WiSE systems. Affected devices have not impacted patient health or safety to date and EBR is working closely with relevant clinical sites and regulatory bodies to provide patient management recommendations. EBR does not expect this development to materially impact the timing or data of headline results for the pivotal SOLVE trial, which remain on track for release in H1 2023. The Company has engaged with the relevant regulatory bodies and expects resolution of this matter prior to final PMA submission to the FDA in H2 2023. EBR does not expect the issue to have a material impact on funding requirements, with the Company's strong cash position (US$79.3m as of 30 June 2022) sufficient to support the pathway to FDA approval and commercialisation.

21/10/2022

The company invites shareholders and investors to a live webinar scheduled on: Friday, 21 October 2022 at 9.15am "“ 9.45am AEDT. The webinar will last for 30 minutes.

20/10/2022

The securities of EBR Systems, Inc. will be suspended from quotation immediately under Listing Rule 17.2, at the request of EBR, pending the release of an announcement regarding a potential manufacturing change to EBR's product.

14/10/2022

listed entity carried for record purposes only

24/11/2021

 

Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.

 

Company Updates

Post your comments here

Please read our Terms before posting comments.
OMISSIONS
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...

     


     

    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    DATEDIRECTORNUMBERPRICEAMOUNT
    15/03/2024Bronwyn Evans17,413$0.715
    CDI
    $12,450
    06/03/2024Bronwyn Evans22,033$0.810
    CDI
    $17,847
    27/11/2023Bronwyn Evans5,000$0.609
    CDI
    $3,043
    22/11/2023Bronwyn Evans20,000$0.648
    CDI
    $12,961
    06/03/2023Bronwyn Evans8,963$0.670
    CDI
    $6,005

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    NAMETITLEDATE OF APPT
    Allan WillExecutive Chairman24/11/2021
    John McCutcheonPresident, Director24/11/2021
    Michael HendricksonCOO29/11/2021
    Gary DohertyCFO11/09/2023
    Trevor MoodyNon Exec Director24/11/2021
    Chris NaveNon Exec Director24/11/2021
    Karen DrexlerNon Exec Director24/11/2021
    David SteinhausNon Exec Director24/11/2021
    Bronwyn EvansNon Exec Director24/11/2021

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    NAMETITLEDATE OF APPOINTMENTDATE OF RESIGNATION
    Frank HettmannCFO24/11/202111/09/2023

    Date of first appointment, title may have changed.